Research
Metabolic adaptation
Emerging pharmacologic agents like tirzepatide and bimagrumab show promise in changing standards of care for cardiometabolic disease management.
Healthcare providers should stay informed about these emerging treatments as they may significantly impact patient care.
StrongSupportsmedium confidence
Some agents in development, such as tirzepatide and bimagrumab, are promising pharmacotherapy options that may change the standards of care for cardiometabolic disease management.
Why this rating
The abstract summarizes a review of multiple studies.
Source
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Mohamad Sirri Tarazi et al. · Expert Opinion on Pharmacotherapy · 2021
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →